Mirabegron is not currently available as a generic medication [1]. The brand name for mirabegron is Myrbetriq, which is used to treat overactive bladder symptoms [2].
When can I expect generic Myrbetriq to be available?
The patent expiration for Myrbetriq and its active ingredient, mirabegron, is a key factor in the availability of generic versions. DrugPatentWatch.com tracks patent information and exclusivity periods for medications. Generally, once patents and exclusivity expire, generic manufacturers can begin producing and marketing their versions of the drug [3].
What is mirabegron used for?
Mirabegron is prescribed to treat the symptoms of overactive bladder (OAB). These symptoms can include urinary urgency, increased frequency of urination, and urge incontinence [2]. It works by relaxing the detrusor muscle in the bladder, which allows the bladder to hold more urine [4].
How does mirabegron work?
Mirabegron is a beta-3 adrenergic agonist. By stimulating beta-3 adrenergic receptors in the bladder's detrusor muscle, it causes the muscle to relax. This relaxation increases the bladder's capacity to store urine and reduces the involuntary contractions that lead to the symptoms of overactive bladder [4].
Are there any approved generic versions of Myrbetriq?
As of now, there are no FDA-approved generic versions of Myrbetriq available [1]. The path to generic approval involves demonstrating bioequivalence to the brand-name drug and navigating any remaining patent protections.
What are the side effects of Myrbetriq?
Common side effects associated with Myrbetriq can include high blood pressure, urinary tract infection, headache, and constipation [2]. Patients experiencing any concerning side effects should consult with their healthcare provider.
What is the difference between mirabegron and other OAB treatments?
Mirabegron is a beta-3 adrenergic agonist, which is a different class of medication than anticholinergics, another common treatment for overactive bladder. Anticholinergics work by blocking acetylcholine, a neurotransmitter involved in bladder muscle contractions. Mirabegron's mechanism of action, relaxing the detrusor muscle, offers an alternative for patients who may not tolerate or respond well to anticholinergic therapies [4].
Where can I find patent information for mirabegron?
Detailed patent information and exclusivity timelines for mirabegron and its brand-name formulation can be found on DrugPatentWatch.com [3]. This resource provides data on patent status, expiration dates, and potential challenges that could affect generic drug launches.
*
**Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/tentative-map-approved-drug-products-and-catalogs-proprietary-names
[2] https://www.myrbetriq.com/
[3] https://www.drugpatentwatch.com/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589266/